SCHEMBL6493586

SCHEMBL6493586

NC(=O)c1[c]c(C(F)(F)F)ccn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.36
NOS3 P29474 1/20 0.35
NOS2 P35228 1/20 0.35
HTT P42858 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MKNK1 Q9BUB5 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
NR3C2 P08235 4/20 0.33
KDM4E B2RXH2 2/20 0.33
CDC7 O00311 1/20 0.32
CCNE1 P24864 1/20 0.32
CDK2 P24941 1/20 0.32
DBF4 Q9UBU7 1/20 0.32
CCNC P24863 1/20 0.32
CDK8 P49336 1/20 0.32
KMO O15229 1/20 0.32
CTNNB1 P35222 1/20 0.32
WNT3A P56704 1/20 0.32
CNR2 P34972 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1551487 0.73 MKNK1 (0.41) L3MBTL1MKNK1MKNK2KDM4ECDC7
SCHEMBL3232701 0.72 SIRT3 (0.36) KMT2AL3MBTL1NOS3NOS2MKNK1
SCHEMBL2586506 0.72 CDK8 (0.38) L3MBTL1MKNK1MKNK2KDM4ECDC7
SCHEMBL11907122 0.69 NOS3 (0.35) NOS3NOS2MKNK1MKNK2CDC7
SCHEMBL602198 0.69 NOS3 (0.38) NOS3NOS2
SCHEMBL1881445 0.69 NOS3 (0.38) NOS3NOS2
SCHEMBL14353433 0.68 KDM4E (0.37) L3MBTL1HTTMKNK1MKNK2KDM4E
SCHEMBL3355639 0.68 KDM4E (0.39) L3MBTL1NOS3NOS2MKNK1MKNK2
SCHEMBL790082 0.67 NOS3 (0.36) NOS3NOS2
SCHEMBL791272 0.67 NOS3 (0.36) KMT2ANOS3NOS2HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005040136-A1 PIPERAZINE DERIVATIVES AND THEIR USE AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2005-05-06 WO disclosed
US-20050096323-A1 Diketopiperazine derivatives to inhibit thrombin NOVOSCIENCE PHARMA INC. (CA) 2005-05-05 US disclosed
EP-1261608-B1 DIKETOPIPERAZINE DERIVATIVES TO INHIBIT THROMBIN BEST EXPRESS WORLDWIDE LTD TRU (VG) 2004-04-28 EP disclosed
US-20030100562-A1 Diketopiperazine derivatives to inhibit thrombin NOVOSCIENCE PHARMA INC. (CA) 2003-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096323-A1 Diketopiperazine derivatives to inhibit thrombin F3, F2, TFPI KMT2A 858/4885L3MBTL1 1620/4885NOS3 3027/4885
US-20030100562-A1 Diketopiperazine derivatives to inhibit thrombin TFPI, F2, F3 KMT2A 982/4885L3MBTL1 2366/4885NOS3 3525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.